stockrow
Saturday 7 November 2026
Export LABT’s income statement to Excel — free account
Lakewood-Amedex Biotherapeutics Inc.
LABT Healthcare Biotechnology
0.37
0.17
−31.48%
Follow LABT
Alert me
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
0.13 | 1.55 |
Net Debt/EBITDA |
0.06 | 0.17 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.33 | 0.83 |
Capex/Depreciation |
0.00 | (0.03) |
Interest Coverage |
(37.39) | (805.36) |
| 749.24% | 0.00% | |
| (753.49%) | 0.00% | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
279.73% | (2,386.22%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(2.79) | (8.29) |
Cash per Share |
0.34 | 0.99 |
Shareholders Equity per Share |
(2.82) | 0.59 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(2.82) | 0.59 |
Free Cash Flow |
(1.94) | (5.73) |
Working Capital |
(2.10) | 0.27 |
Capital Expenditures |
— | 0.00 |
Net Current Asset Value |
(2.14) | 0.11 |
| Other line items | ||
Quick Ratio |
0.10 | 1.36 |
Depreciation/Fixed assets |
13.04 | 3.75 |
Cash ROIC |
112.53% | (524.90%) |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(2.79) | (8.28) |
Capex per Share |
0.00 | 0.00 |
Average Payables |
0.27 | — |
Average Assets |
0.78 | — |
Average Common Equity |
(0.78) | — |
Capex to Sales |
— | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026